Cytokinetics
CYTK
250 hedge funds and large institutions have $3.22B invested in Cytokinetics in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 94 increasing their positions, 78 reducing their positions, and 27 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
21% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 78
0.15% more ownership
Funds ownership: 113.68% → 113.83% (+0.15%)
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
1% less funds holding
Funds holding: 253 → 250 (-3)
9% less capital invested
Capital invested by funds: $3.55B → $3.22B (-$329M)
48% less call options, than puts
Call options by funds: $29.8M | Put options by funds: $57.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$42.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.7M |
| 3 |
Barclays
London,
United Kingdom
|
+$14.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$13.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$36.3M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$16.6M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.3M |
| 4 |
Goldman Sachs
New York
|
-$13.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$10.6M |
CYTK Hedge Fund Activity: Q3 2023 in Review
250 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2023, worth a combined $3.22B — down 9.3% from $3.55B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CYTK and 26 opened new positions — a net loss of 1 holder — while 78 trimmed existing stakes and 94 added.
The largest buyer was Marshall Wace, adding an estimated $42.6M. The largest seller was Lord, Abbett & Co, cutting an estimated $36.3M.
- 250 institutional investors held Cytokinetics (CYTK) as of Q3 2023, down from 253 in Q2 2023.
- Funds reported $3.22B of Cytokinetics stock for Q3 2023, down 9.3% quarter-over-quarter.
- 26 funds opened new Cytokinetics positions in Q3 2023 and 27 closed out, a net change of -1 holder.
- The largest Cytokinetics buyer in Q3 2023 was Marshall Wace, an estimated $42.6M added.
- The largest Cytokinetics seller in Q3 2023 was Lord, Abbett & Co, an estimated $36.3M sold.
Based on aggregated 13F filings for Q3 2023.